Wild-type human hepatitis B virus (HBV) exhibits selective export of virions containing mature genomes. In contrast, changing an isoleucine to a leucine at amino acid 97 (I97L) of the HBV core antigen (HBcAg) causes it to release immature genomes. To elucidate the structure-function relationship of HBcAg at amino acid 97, we systematically replaced the isoleucine residue at this position with 18 other amino acids via mutagenesis. Twelve of the 18 mutants exhibited no significant phenotype, while five new mutants displayed strong phenotypes. The I97D mutant had a near lethal phenotype, the I97P mutant exhibited a significantly reduced level of virion secretion, and the I97G mutant lacked the full-length relaxed circular form of viral DNA. The tip of the spike of the capsid particle is known to contain a predominant B-cell epitope. However, the recognition of this exposed epitope by an anti-HBc antibody appeared to be affected by the I97E mutation or by histidine tagging at the C terminus of mutant HBcAg, which is presumably in the capsid interior. Surprisingly, the nuclear HBcAg of mutants I97E and I97W, produced from either a replicon or an expression vector, was found to be colocalized with nucleolin and B23 at a frequency of nearly 100% by confocal immunofluorescence microscopy. In contrast, this colocalization occurred with wild-type HBcAg only to a limited extent. We also noted that nucleolin-colocalizing cells were often binucleated or apoptotic, suggesting that the presence of HBcAg in the nucleolus may perturb cytokinesis. The mechanism of this phenomenon and its potential involvement in liver pathogenesis are discussed. To our knowledge, this is the first report of nucleolar HBcAg in culture.Hepatitis B virus (HBV) is a major human infectious pathogen that was first discovered in leukemia patients and Australian aboriginals in 1965 (3). More than one-third of the world's population has been infected with HBV (77). Chronic active hepatitis associated with HBV infection often leads to the development of cirrhosis, liver failure, and highly malignant liver cancer (1, 2, 6, 23). In part because of the emergence of drug-resistant HBV variants, current treatments for hepatitis B have a disappointingly low efficacy compared to those for hepatitis C (9, 33). A new target, other than HBV polymerase, needs to be identified for therapeutic treatment. A better basic understanding of the life cycle of HBV, including the functional significance of HBV variants and the mechanism of virion secretion, might lead to new clinical interventions for chronic infections with HBV.The release of HBV virions from hepatocytes is a tightly regulated event. The current dogma indicates that the mature HBV genome is preferentially exported from the intracellular compartment (24,48,60,65). Recently, members of our laboratory identified an immature secretion phenotype of a highly frequent naturally occurring HBV variant containing a leucine residue at amino acid 97 of the core protein. Unlike wild-type HBV, this 97L variant secretes alm...